H
Hoang Q. Nguyen
Researcher at University of Texas MD Anderson Cancer Center
Publications - 14
Citations - 786
Hoang Q. Nguyen is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Sample size determination & Acute leukemia. The author has an hindex of 9, co-authored 14 publications receiving 690 citations.
Papers
More filters
Journal ArticleDOI
Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.
Marcos de Lima,Sergio Giralt,Peter F. Thall,Leandro de Padua Silva,Roy B. Jones,Krishna V. Komanduri,Thomas Braun,Hoang Q. Nguyen,Richard E. Champlin,Guillermo Garcia-Manero +9 more
TL;DR: The authors hypothesized that low‐dose azacitidine administered after transplant would reduce recurrence rates, and conducted a study to determine a safe dose/schedule combination.
Journal ArticleDOI
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.
Marina Konopleva,Peter F. Thall,Cecilia Arana Yi,Gautam Borthakur,Andrew Coveler,Carlos E. Bueso-Ramos,Juliana Benito,Sergej Konoplev,Yongchuan Gu,Farhad Ravandi,Elias Jabbour,Stefan Faderl,Deborah A. Thomas,Jorge E. Cortes,Tapan M. Kadia,Steven M. Kornblau,Naval Daver,Naveen Pemmaraju,Hoang Q. Nguyen,Jennie Feliu,Hongbo Lu,Caimiao Wei,William R. Wilson,Teresa J. Melink,John Gutheil,Michael Andreeff,Elihu H. Estey,Hagop M. Kantarjian +27 more
TL;DR: Findings indicate that hypoxia is a prevalent feature of the leukemic microenvironment and that targeting hypoxian with hypoxIA-activated prodrugs warrants further evaluation in acute leukemia.
Book
Bayesian Designs for Phase I-II Clinical Trials
TL;DR: Chapter 10 Chemical Quantities Answers Prentice Hall Chemistry Review Answers Chapter 12 Section 3 Solutions Chapelle Vence Journal Dune Creation Matisse Chapter 11 Cell Communication Study Answers Chapter 07 Measurement Joneslabs Chapter 1 The Civil War Fte Chapter 11 Stoichiometry Study Chapter 11 The Mole answers.
Journal ArticleDOI
Adaptive randomization to improve utility-based dose-finding with bivariate ordinal outcomes.
Peter F. Thall,Hoang Q. Nguyen +1 more
TL;DR: In this paper, a sequentially outcome-adaptive Bayesian design is proposed for choosing the dose of an experimental therapy based on elicited utilities of a bivariate ordinal (toxicity, efficacy) outcome.
Journal ArticleDOI
Patient‐Specific Dose Finding Based on Bivariate Outcomes and Covariates
TL;DR: A Bayesian sequential dose-finding procedure based on bivariate (efficacy, toxicity) outcomes that accounts for patient covariates and dose‐covariate interactions is presented and is illustrated by a dose‐finding trial in acute leukemia.